HC Wainwright Has Negative Forecast for SMMT FY2025 Earnings

Summit Therapeutics PLC (NASDAQ:SMMT) – Analysts at HC Wainwright dropped their FY2025 EPS estimates for Summit Therapeutics in a research report issued to clients and investors on Tuesday, October 21st. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($1.47) for the year, down from their prior estimate of ($1.03). HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Summit Therapeutics’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Summit Therapeutics’ Q4 2025 earnings at ($0.31) EPS, Q1 2026 earnings at ($0.31) EPS, Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.34) EPS and FY2026 earnings at ($1.28) EPS.

Summit Therapeutics (NASDAQ:SMMT) last announced its quarterly earnings data on Monday, October 20th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.17).

Several other equities research analysts have also weighed in on SMMT. Piper Sandler began coverage on shares of Summit Therapeutics in a report on Monday, August 18th. They issued a “neutral” rating and a $21.00 target price on the stock. Summit Redstone set a $13.00 target price on shares of Summit Therapeutics in a report on Tuesday, September 16th. Guggenheim reiterated a “buy” rating and issued a $40.00 target price on shares of Summit Therapeutics in a report on Wednesday. Barclays increased their target price on shares of Summit Therapeutics from $13.00 to $16.00 and gave the stock an “underweight” rating in a report on Tuesday. Finally, UBS Group began coverage on shares of Summit Therapeutics in a report on Tuesday, July 1st. They issued a “buy” rating and a $30.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat, Summit Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $31.14.

Summit Therapeutics Stock Performance

Shares of SMMT stock opened at $19.16 on Thursday. Summit Therapeutics has a 52-week low of $15.55 and a 52-week high of $36.91. The stock has a market cap of $14.26 billion, a PE ratio of -15.45 and a beta of -1.13. The firm’s 50 day moving average price is $22.02 and its two-hundred day moving average price is $23.36.

Insiders Place Their Bets

In related news, CEO Mahkam Zanganeh acquired 5,000 shares of the company’s stock in a transaction that occurred on Thursday, September 11th. The shares were acquired at an average cost of $18.07 per share, for a total transaction of $90,350.00. Following the completion of the acquisition, the chief executive officer directly owned 556,093,090 shares in the company, valued at approximately $10,048,602,136.30. The trade was a 0.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Robert W. Duggan acquired 5,000 shares of the company’s stock in a transaction that occurred on Thursday, September 11th. The shares were bought at an average price of $18.07 per share, for a total transaction of $90,350.00. Following the completion of the acquisition, the chief executive officer owned 556,093,090 shares of the company’s stock, valued at $10,048,602,136.30. This trade represents a 0.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 676,788 shares of company stock worth $11,969,512. 84.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Summit Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in SMMT. Janney Montgomery Scott LLC raised its holdings in shares of Summit Therapeutics by 12.1% during the first quarter. Janney Montgomery Scott LLC now owns 17,610 shares of the company’s stock worth $340,000 after acquiring an additional 1,894 shares during the period. Golden State Wealth Management LLC increased its stake in Summit Therapeutics by 100.0% in the 1st quarter. Golden State Wealth Management LLC now owns 1,502 shares of the company’s stock valued at $29,000 after buying an additional 751 shares during the last quarter. Lisanti Capital Growth LLC acquired a new stake in Summit Therapeutics in the 1st quarter valued at $1,039,000. Sovran Advisors LLC increased its stake in Summit Therapeutics by 25.1% in the 1st quarter. Sovran Advisors LLC now owns 146,528 shares of the company’s stock valued at $2,827,000 after buying an additional 29,354 shares during the last quarter. Finally, Principal Financial Group Inc. increased its stake in Summit Therapeutics by 20.1% in the 1st quarter. Principal Financial Group Inc. now owns 246,429 shares of the company’s stock valued at $4,754,000 after buying an additional 41,279 shares during the last quarter. 4.61% of the stock is currently owned by institutional investors and hedge funds.

About Summit Therapeutics

Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company’s lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.